Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Frontiers | Systematic Review of Safety and Efficacy of Atacicept in ...
Atacicept • Vera Therapeutics
Vera Therapeutics’ Atacicept Shines at ASN Kidney Week 2025 - Investors ...
Vera Therapeutics' Atacicept Shows Promising Results in Phase 2b ORIGIN ...
Atacicept Phase 3 Data Highlights Vera Therapeutics' Path to Potential ...
Atacicept in IgAN - Vera Therapeutics
Vera Therapeutics: Atacicept Cuts Proteinuria 42% in Phase 3 | VERA ...
Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept
Vera Therapeutics Announces Expanded Atacicept Development
Atacicept in LN - Vera Therapeutics
New Hope for Kidney Disease: Vera Therapeutics’ Atacicept Advances ...
Vera Therapeutics Reports the US FDA’s BLA Submission for Atacicept to ...
atacicept (VT-001) / EMD Serono, Vera Therap
Video: Vera Therapeutics Stock Skyrockets 88% on Atacicept Success!
Vera's Atacicept on Fast Track for Kidney Disease Approval ...
Atacicept – Application in Therapy and Current Clinical Research
Atacicept Phase 3 Trial Shows 46% Kidney Disease Improvement in IgA ...
Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN
Vera Builds ‘Compelling Profile’ for Atacicept in IgAN, Eyes Q4 Filing ...
Atacicept (TACI-Ig) | B Cell Stimulator | MedChemExpress
(PDF) Atacicept in multiple sclerosis (ATAMS): a randomised, placebo ...
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo ...
Atacicept Shot Significantly Reduces Proteinuria in IgA Nephropathy: NEJM
Efficacy and safety of atacicept for prevention of flares in patients ...
Atacicept - Wirkung, Anwendung & Risiken | MedLexi.de
Atacicept for IgA nephropathy succeeds in phase III trial ...
Atacicept for IgA Nephropathy: Long-Term Results from the ORIGIN Phase ...
Atacicept in combination with MMF and corticosteroids in lupus ...
Vera’s Atacicept Excels in IgA Nephropathy Trial | Perigon
Safety and Efficacy of Atacicept in Combination With Rituximab for ...
atacicept | PDF | Medical Specialties | Clinical Medicine
Study on the Effects of Atacicept in Adults with IgA Nephropathy
ORIGIN 3 Clinical Trial Evaluating Atacicept in Adults With IgA ...
Frontiers | Kinetics of free and ligand-bound atacicept in human serum
(PDF) Atacicept in combination with MMF and corticosteroids in lupus ...
Population pharmacokinetics of atacicept in systemic lupus ...
Atacicept Mechanism of Action - YouTube
(PDF) Reduced B lymphocyte and immunoglobulin levels after atacicept ...
Understanding Atacicept & 36-Week ORIGIN 3 Data from Kidney Week 2025 ...
Randomized Phase II JANUS Study of Atacicept in Patients With IgA ...
(PDF) Population pharmacokinetics of atacicept in systemic lupus ...
Atacicept reduces proteinuria for adults with IgA nephropathy
(PDF) Systematic Review of Safety and Efficacy of Atacicept in Treating ...
Phase 3 ORIGIN Sets Stage for Atacicept in IgA Nephropathy, with ...
Randomized Clinical Trial of Atacicept for Treatment of IgA Nephropathy ...
Atacicept in IgA Nephropathy: Analysis of the Interim Phase 3 Data in ...
Atacicept in patients with rheumatoid arthritis and an inadequate ...
(PDF) Phase I Clinical Study of Atacicept in Patients with Relapsed and ...
Atacicept prevents B cell repopulation but not isotype switching or ...
Atacicept: targeting B cells in multiple sclerosis - PMC
10亿美元分子：Vera大涨49%，Atacicept治疗IgA肾病2b期临床成功 Armstrong 2023年1月25日， Vera ...
Vera Therapeutics: Waiting For A Pullback (NASDAQ:VERA) | Seeking Alpha
Vera Therapeutics: Stock Rises As IgAN Approval Chances Increase - I'm ...
Science • Vera Therapeutics
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase ...
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN ...
Vera Therapeutics Announces Positive Week 36 Efficacy and
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b ...
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial ...
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid ...
Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug ...
Vera Therapeutics' Atacicept: A Breakthrough in IgAN and a Catalyst for ...
Vera Therapeutics Receives Priority Review for Atacicept, Shares Advance
Vera Therapeutics' Atacicept: A Groundbreaking Step Toward FDA Approval ...
Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA ...
Atacicept: Uses, Dosage, Side Effects, Food Interaction & FAQ
Vera Therapeutics In-Person R&D Day: Week 72 Data from Phase 2b ORIGIN ...
How Does Vera Therapeutics' Presentation Design Highlight Atacicept’s ...
© 2023 VERA THERAPEUTICS, INC.
A phase 2b, randomized, double-blind, placebo-controlled, clinical ...
PPT - USING BIOMARKERS FOR EARLY PHASE DOSE SELECTION WITH PROTEIN ...
Results of Open-label Extension of the ORIGIN Study - Explore the ...
FDA已授予Atacicept用于治疗免疫球蛋白A肾病 (IgAN)_阿塞西普_试验_Vera
WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of ...
Behind The Volatility Of Vera Therapeutics (NASDAQ:VERA) | Seeking Alpha
Povetacicept，一种增强型 APRIL/BAFF 双重拮抗剂，可调节 B 淋巴细胞和致病性自身抗体，用于治疗狼疮和其他 B 细胞相关 ...
WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ...
In-Person R&D Day: Week 72 Data from Phase 2b ORIGIN Clinical Trial of ...
Atacicept: Uses, Interactions, Mechanism of Action | DrugBank Online
Lupus Patients with High Disease Activity Show 'Significant Improvement ...
